Question Bank › Named catch-up gap

Named catch-up gap

Named catch-up gap: management identifies where the company visibly lags peers or its own potential, and is already clos

Calls Tested
500
Answered YES
24
Hit Rate
4.8%
rare by design

Supernus Pharmaceuticals, Inc. (SUPN) — this company's answers

NO on the Q3 2016 call 2016-11-18 D
The model's full reasoning — Q3 2016 call → NO我们需要判断管理层是否在电话会议中明确指出公司当前在某个具体维度上表现不佳（相对于同行、行业常态或公司自身潜力），并描述了已经进行的改进工作，且管理层将其视为不依赖市场条件改善的有意义改进来源。我们只使用提供的文字记录。 仔细阅读文字记录。Jack Khattar和Greg Patrick讨论了业务更新。主要点是强劲增长、产品处方、财务业绩、管线进展（SPN-810和SPN-812）、知识产权诉讼、业务发展。 他们是否明确指出公司落后于某个具体维度？例如，他们谈论了SPN-810的入组问题。他们提到“改善入组和保留率的措施”，并与外部机构合作，延长筛查期等。他们承认之前入组存在问题，并正在努力改善。然而，这是否构成“具体命名的不佳维度”？他们确实说“采取措施改善入组和保留率”，但没有明确指明公司相对于同行或自身潜力表现不佳。他们也没有量化差距。他们只是说“入组预期将持续到2017年”，但提到早期结果改善。这更像是艰难临床试验的预期困难，而不是“公司表现不佳”的清晰诊断。 其他可能的领域：毛利率、净销售？他们提高了全年净销售指引，提到毛净扣减。没有具体不及之处。 也许关于SPN-812的正面数据是优势，不是不足。 关于“第四季度销售费用的增加”等是正常运营。 因此，他们是否明确指出公司相对同行表现不佳？没有。他们谈论“增长”和“改善”但未承认具体不足，除了SPN-810入组，但他们将其表述为行动改善情况，而非负面比较。此外，这是否属于“不依赖市场条件”？临床试验入组不是市场条件。但管理层是否将其视为有意义改进？他们谈论2024年入组继续，但未给出目标差距。 问题问的是“具体命名的不佳维度”。我没有看到。他们提到“入组较慢”，但未称其为相对于同行或自身的差距。他们说的是“入组速度慢于预期”，但未量化或命名基准。 因此，答案应为NO。

← Back to the full SUPN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management IDENTIFY A SPECIFIC, NAMED DIMENSION ON WHICH THE COMPANY CURRENTLY UNDERPERFORMS — relative to industry peers, industry norms, or the company's own demonstrated potential elsewhere in its business — AND describe work ALREADY UNDERWAY to close that specific gap, with management treating the closing of it as a meaningful source of improvement that does not depend on market conditions getting better? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent self-diagnosis with both halves present: (1) A NAMED GAP, OWNED BY MANAGEMENT: management itself states, concretely, where the company lags — for example margins, productivity, utilization, pricing, mix, service levels, penetration of its own customer base, or performance of one region, segment, or facility versus the company's own better ones or versus what peers demonstrably achieve — identified specifically enough that a reader knows exactly what is deficient and roughly how large the shortfall is; and (2) CLOSING WORK IN MOTION WITH THE MECHANISM EXPLAINED: management describes the concrete actions already executing to close it — not aspirations — and conveys why the gap is closable by the company's own effort (the better level is already achieved by peers or by the company's own best operations, so the target is demonstrated rather than theoretical), with early progress or a credible operational path visible in the current period. Answer NO if management only claims general improvement opportunity without naming a specific measurable gap. NO if the gap is blamed on external conditions that must improve. NO if the closing work is only planned, promised, or under study. NO if the gap-closing is ordinary cost-cutting rhetoric with no named benchmark. NO if the diagnosis appears only in an analyst's question that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
MEG Montrose Environmental Group, Inc. Q3 2023 2023-11-08 C+
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
CMG Chipotle Mexican Grill, Inc. Q3 2023 2023-10-27 B+
SWK Stanley Black & Decker, Inc. Q1 2023 2023-05-04 D
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
KD Kyndryl Holdings, Inc. Q4 2021 2022-03-01 C+
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
HNRG Hallador Energy Company Q3 2021 2021-11-09 C+
LPTH LightPath Technologies, Inc. Q4 2021 2021-09-09 D
KOP Koppers Holdings Inc. Q2 2018 2018-08-12 C+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
ACHC Acadia Healthcare Company, Inc. Q4 2017 2018-02-22 C+
ADNT Adient plc Q1 2018 2018-01-29 D
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
STKL SunOpta Inc. Q2 2017 2017-08-09 C+
PTC PTC Inc. Q3 2017 2017-07-19 C+
ABM ABM Industries Incorporated Q2 2017 2017-06-08 B
PPG PPG Industries, Inc. Q1 2017 2017-04-20 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
SXT Sensient Technologies Corporation Q4 2016 2017-02-10 A
BC Brunswick Corporation Q3 2016 2016-10-28 B+
SON Sonoco Products Company Q4 2015 2016-02-11 B

How the model reasoned

HOLX · Q4 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly diagnosing Cynosure’s commercial organization as the specific underperforming dimension (salesforce turnover, recruiting, and productivity lagging behind the company’s international business and its own best operations). They then describe concrete, already-executing actions—stopping voluntary turnover, rehiring high performers, instituting 90-day reviews, new compensation, and building “Cynosure 2.0”—as the mechanism to close the gap.
STKL · Q2 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management identifying a specific named gap in the bars segment, where operational issues at a particular facility are causing inefficient production and gross margin losses. They describe a rapid recovery team already executing systematic identification and correction of these issues, treating the gap as closable through their own operational efforts rather than external market improvements — this aligns with the criteria for a meaningful source of improvement.
ADNT · Q1 2018 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly naming the Seat Structures and Mechanisms (SS&M) business as the specific underperforming dimension. They state it is “destroyed shareholder value” when run as currently organized, and that it is “impacting our financial results” with “significant impact.

More from the question bank

Paid to expand: the company's growth spendinThe product is disappearing into reorder rhyRecently unlocked doorWorking for customers it could not have servVolume records through a still-fixed gateTwo-sided intensityAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.